论文部分内容阅读
目的:观察复方夏天无片联合来氟米特治疗类风湿关节炎的临床疗效及安全性。方法:将72例患者随机分为2组各36例,治疗组予复方夏天无片联合来氟米特治疗,对照组予洛索洛芬钠片加来氟米特治疗,比较治疗前后临床疗效及血沉(ESR)、C-反应蛋白(CRP)、类风湿因子(RF)、抗环瓜氨酸肽(CCP)抗体等实验室指标变化。结果:总有效率治疗组为91.67%,对照组为88.89%,2组比较,差异无显著性意义(P>0.05)。治疗后2组ESR、CRP、RF(对照组除外)、抗CCP抗体均较治疗前有明显改善,差异有显著性或非常显著性意义(P<0.05,P<0.01);且治疗组中RF指标改善较对照组更显著,差异有显著性意义(P<0.05)。不良反应发生率治疗组为8.33%,对照组为16.67%,2组比较,差异有显著性意义(P<0.05)。结论:复方夏天无联合来氟米特治疗类风湿关节炎安全有效。
OBJECTIVE: To observe the clinical efficacy and safety of compound non-tablet combined with leflunomide in the treatment of rheumatoid arthritis in summer. Methods: Seventy-two patients were randomly divided into two groups (n = 36 each). The treatment group was treated with compound-free summer combined with leflunomide, while the control group was treated with loxoprofen sodium plus leflunomide. The clinical efficacy was compared between before and after treatment (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) Results: The total effective rate was 91.67% in the treatment group and 88.89% in the control group. There was no significant difference between the two groups (P> 0.05). After treatment, ESR, CRP, RF (except control group) and anti-CCP antibody in two groups were significantly improved compared with before treatment, the difference was significant or very significant (P <0.05, P <0.01) The index improvement was more significant than the control group, the difference was significant (P <0.05). The incidence of adverse reactions was 8.33% in the treatment group and 16.67% in the control group. There was significant difference between the two groups (P <0.05). Conclusion: The compound summer leflunomide treatment of rheumatoid arthritis is safe and effective.